{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:19:39Z","timestamp":1794565179074,"version":"4.9.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["trasci.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.transci.2024.104052","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T01:18:31Z","timestamp":1734398311000},"page":"104052","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness of ibrutinib in the management of chronic GVHD"],"prefix":"10.1016","volume":"64","author":[{"given":"Mehmet Ali","family":"Erkurt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Sarici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulkadir","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilhami","family":"Berber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulten","family":"Korkmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Kuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Sinan","family":"Dal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serdal","family":"Korkmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Turgay","family":"Ulas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fevzi","family":"Altuntas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.transci.2024.104052_bib1","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1056\/NEJMra1703472","article-title":"Pathophysiology of chronic graft-versus-host disease and therapeutic targets","volume":"377","author":"Zeiser","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.transci.2024.104052_bib2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2018-10-879429","article-title":"Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia","volume":"133","author":"Burger","year":"2019","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.transci.2024.104052_bib3","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.transci.2024.104052_bib4","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.bbmt.2014.10.021","article-title":"Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research","volume":"21","author":"Arai","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"10.1016\/j.transci.2024.104052_bib5","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.beha.2010.09.016","article-title":"Have we made progress in the management of chronic graft-vs-host disease?","volume":"23","author":"Lee","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"issue":"17","key":"10.1016\/j.transci.2024.104052_bib6","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1182\/blood-2010-11-319509","article-title":"Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium","volume":"117","author":"Pidala","year":"2011","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.transci.2024.104052_bib7","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1182\/bloodadvances.2021004941","article-title":"Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium","volume":"5","author":"DeFilipp","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.transci.2024.104052_bib8","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"10.1016\/j.transci.2024.104052_bib9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2016-08-686659","article-title":"Mechanistic approaches for the prevention and treatment of chronic GVHD","volume":"129","author":"Cutler","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.transci.2024.104052_bib10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood.V100.1.48","article-title":"Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone","volume":"100","author":"Koc","year":"2002","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.transci.2024.104052_bib11","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","article-title":"EBMT\u2212 NIH\u2212 CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment","volume":"53","author":"Schoemans","year":"2018","journal-title":"Bone Marrow Transpl"},{"issue":"21","key":"10.1016\/j.transci.2024.104052_bib12","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1182\/blood-2009-02-202937","article-title":"Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease","volume":"113","author":"Martin","year":"2009","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.transci.2024.104052_bib13","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1053\/bbmt.2001.v7.pm11400948","article-title":"Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease","volume":"7","author":"Arora","year":"2001","journal-title":"Biol Blood Marrow Transpl"},{"key":"10.1016\/j.transci.2024.104052_bib14","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1007\/s11136-020-02448-y","article-title":"FDA review summary of patient-reported outcome results for ibrutinib in the treatment of chronic graft versus host disease","volume":"29","author":"King-Kallimanis","year":"2020","journal-title":"Qual Life Res"},{"issue":"10","key":"10.1016\/j.transci.2024.104052_bib15","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/ajh.27040","article-title":"Updates in chronic graft-versus-host disease management","volume":"98","author":"Malard","year":"2023","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.transci.2024.104052_bib16","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1038\/s41409-021-01389-5","article-title":"Steroid-refractory chronic graft-versus-host disease: treatment options and patient management","volume":"56","author":"Wolff","year":"2021","journal-title":"Bone Marrow Transpl"},{"key":"10.1016\/j.transci.2024.104052_bib17","unstructured":"\u3008https:\/\/www.rxabbvie.com\/pdf\/imbruvica_pi.pdf\u3009; 2022."},{"issue":"6","key":"10.1016\/j.transci.2024.104052_bib18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/oncolo\/oyac042","article-title":"FDA approval summary: ruxolitinib for treatment of chronic graft-versus-host disease after failure of one or two lines of systemic therapy","volume":"27","author":"Le","year":"2022","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.transci.2024.104052_bib19","article-title":"Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease","volume":"70","author":"Ali","year":"2022","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.transci.2024.104052_bib20","first-page":"1","article-title":"Updates in chronic graft-versus-host disease: novel treatments and best practices in the current era","author":"Vadakkel","year":"2024","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"10.1016\/j.transci.2024.104052_bib21","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jtct.2021.03.033","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IIa. The 2020 clinical implementation and early diagnosis working group report","volume":"27","author":"Kitko","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"3","key":"10.1016\/j.transci.2024.104052_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006398","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology","volume":"11","author":"Naidoo","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10.1016\/j.transci.2024.104052_bib23","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.22.00509","article-title":"Ibrutinib for first-line treatment of chronic graft-versus-host disease: results from the randomized phase III iNTEGRATE study","volume":"41","author":"Miklos","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.transci.2024.104052_bib24","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jtct.2021.08.017","article-title":"Ibrutinib in steroid-refractory chronic graft-versus-host disease, a single-center experience","volume":"27","author":"Chin","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"10","key":"10.1016\/j.transci.2024.104052_bib25","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jtct.2021.05.019","article-title":"An open-label, single-arm, multicenter study of ibrutinib in Japanese patients with steroid-dependent\/refractory chronic graft-versus-host disease","volume":"27","author":"Doki","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"2","key":"10.1016\/j.transci.2024.104052_bib26","doi-asserted-by":"crossref","first-page":"216","DOI":"10.4274\/imj.galenos.2023.98370","article-title":"The experience of ibrutinib in chronic graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation: single center experience","volume":"24","author":"Sar\u0131c\u0131","year":"2023","journal-title":"\u0130stanbul Med J"},{"issue":"10","key":"10.1016\/j.transci.2024.104052_bib27","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/j.bbmt.2019.06.023","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy: 1-year update of a phase 1b\/2 study","volume":"25","author":"Waller","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"10.1016\/j.transci.2024.104052_bib28","first-page":"104","article-title":"Long-term use of Ibrutinib in Japanese patients with steroid dependent\/refractory cGVHD: Final analysis of multicenter study","volume":"6","author":"Toyosaki","year":"2023","journal-title":"Blood Cell Ther"},{"issue":"1","key":"10.1016\/j.transci.2024.104052_bib29","doi-asserted-by":"crossref","first-page":"60","DOI":"10.56875\/2589-0646.1111","article-title":"A Single-center, real-world experience of chronic GVHD Treatment Using Ibrutinib, Imatinib, and Ruxolitinib and its treatment outcomes","volume":"17","author":"Linn","year":"2024","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"11","key":"10.1016\/j.transci.2024.104052_bib30","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jtct.2022.08.021","article-title":"Ibrutinib treatment of pediatric chronic graft-versus-host disease: primary results from the phase 1\/2 iMAGINE Study","volume":"28","author":"Carpenter","year":"2022","journal-title":"Transpl Cell Ther"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050224002337?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050224002337?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T08:48:25Z","timestamp":1738572505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050224002337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1473050224002337"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2024.104052","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of ibrutinib in the management of chronic GVHD","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2024.104052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104052"}}